Endpoint News: A cardiovascular cell therapy player grabs $54M for a new beginning.
19/01/2021
Related news
10/09/2021
Read full article here: https://www.fiercebiotech.com/biotech/ixaka-s-cell-therapy-clears-interim-phase-3-data-review
Read More
08/09/2021
Read full article here: https://www.pharmatimes.com/news/positive_interim_data_for_ixakas_lead_multi-cell_therapy_1376392
Read More
08/09/2021
Read full article here: https://www.thepharmaletter.com/article/ixaka-s-cell-therapy-shows-promise-in-interim-results#:~:text=Private%20UK%2Dbased%20cell%20and,from%20a%20Phase%20III%20trial.&text=The%20product%20is%20produced%20using,enriched%20for%20white%20blood%20cells
Read More